The Phase III global study of EG12014 in patients with early breast cancer.
Phase of Trial: Phase III
Latest Information Update: 15 May 2017
At a glance
- Drugs Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- 15 May 2017 New trial record
- 02 May 2017 According to an EirGenix media release, the design of this Phase III study, along with the regulatory strategy of EG12014 biosimilar program, will be discussed in the regulatory meetings with the EMA and FDA in Q2-Q3, 2017.